Cargando…

Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience

Detalles Bibliográficos
Autores principales:	Zhao, Qian, Li, Feng, Song, Ping, Zhou, Xiaogang, An, Zhiming, Mei, Jiangang, Shao, Jingjing, Li, Hanqing, Wang, Xuli, Guo, Xing, Zhai, Yongping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764140/ https://www.ncbi.nlm.nih.gov/pubmed/31558165 http://dx.doi.org/10.1186/s40880-019-0395-3

Ejemplares similares

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
por: Teramachi, Jumpei, et al.
Publicado: (2023)

The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
por: Szabo, Agoston Gyula, et al.
Publicado: (2019)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

P960: EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.
por: Brioli, Annamaria, et al.
Publicado: (2023)

Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era
por: Nakaya, Aya, et al.
Publicado: (2017)

Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
por: Martino, Massimo, et al.
Publicado: (2020)

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
por: Gao, Wen, et al.
Publicado: (2020)

Is There an Optimal Timing of Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Agents?
por: Toprak, Selami Koçak
Publicado: (2013)

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
por: Zhou, Huixing, et al.
Publicado: (2023)

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
por: Mina, Roberto, et al.
Publicado: (2020)

Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance
por: Qu, Xiaoyan, et al.
Publicado: (2015)

MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis
por: Li, Feng, et al.
Publicado: (2017)

Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture
por: Al Hadidi, Samer, et al.
Publicado: (2017)

Immunoglobulin D Multiple Myeloma: A Rare Variant
por: MacDougall, Kira N, et al.
Publicado: (2022)

Lymphoid morphology, hyperviscosity and extensive immunoglobulin deposits in myeloma
por: Sehgal, Tushar, et al.
Publicado: (2022)

Non-secretory immunoglobulin E myeloma associated with immunoglobulin G monoclonal gammopathy of undetermined significance
por: Yasuyama, Masako, et al.
Publicado: (2012)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2020)

P927: CLINICAL CHARACTERISTICS, SURVIVAL OUTCOMES AND PROGNOSIS IN 123 IMMUNOGLOBULIN D MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER
por: Liu, J., et al.
Publicado: (2022)

Immunoglobulin D-λ/λ biclonal multiple myeloma: A case report
por: He, Qiao-Ling, et al.
Publicado: (2021)

Emerging agents and regimens for multiple myeloma
por: Yang, Yang, et al.
Publicado: (2020)

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation or Treated with Immunomodulatory Agents.
por: Khalafallah, Alhossain, et al.
Publicado: (2010)

Immunoglobulin D Multiple Myeloma With Rapidly Progressing Renal Failure
por: Modi, Jwalant, et al.
Publicado: (2015)

Neutrophilic Urticaria with Systemic Inflammation Associated with Immunoglobulin A Myeloma
por: PAUGOY, Héloïse, et al.
Publicado: (2021)

Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins
por: Soma, Shunsuke
Publicado: (2022)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Monoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center
por: Lin, Zi-Shan, et al.
Publicado: (2021)

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era
por: Chakraborty, R, et al.
Publicado: (2016)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

The Post-Antibiotic Era: A New Dawn for Bacteriophages
por: Jin, Youshun, et al.
Publicado: (2023)

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
por: Swaminathan, Bhairavi, et al.
Publicado: (2015)

The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma
por: Sarı, Murat, et al.
Publicado: (2017)

Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing
por: Chow, Signy, et al.
Publicado: (2022)

Phenotypic Detection of Clonotypic B Cells in Multiple Myeloma by Specific Immunoglobulin Ligands Reveals their Rarity in Multiple Myeloma
por: Trepel, Martin, et al.
Publicado: (2012)

Retroperitoneal fibrosis in the era of immunoglobulin G4-related disease
por: Choi, Yoon Kyung, et al.
Publicado: (2019)

Association of Co-dominant Immunoglobulin G Deposit in Immunoglobulin A Nephropathy With Poor Clinicopathological and Laboratory Parameters
por: Kalita, Pranjal, et al.
Publicado: (2021)

Does Ethnicity Matter in Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents? Evidence From Real-World Data
por: Farswan, Akanksha, et al.
Publicado: (2021)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_93gkvun5i1jg1v0sjhcgad60fj